A Phase Ib Clinical Study of AC-003 Capsules in Subjects With aGVHD.

Inclusion Criteria

• •1. Male or female patients age ≥ 18 years.
• •2. Patients who have undergone allogeneic hematopoietic stem cell transplantation (HSCT) from any donor source (including matched unrelated donor, haplo-identical).
• •3. Diagnosis of grade II-IV aGVHD as per MAGIC criteria within 100 days after HSCT.
• •4. Diagnosis of steroid-refractory or steroid-dependent aGVHD in at least one of the following criteria:
• •1. Progressive Disease, defined as any target organ worsening, after 3 days of initial treatment with methylprednisolone 1\~2 mg/kg/day (or equivalent corticosteroid)
• •2. Not partial response after 7 days of initial treatment with methylprednisolone 1\~2 mg/kg/day (or equivalent corticosteroid)
• •3. Not complete response after 14 days of initial treatment with methylprednisolone 1\~2 mg/kg/day (or equivalent corticosteroid)
• •4. Relapse of aGVHD when corticosteroid tapering.